“HeartMate II has allowed us to bring VAD technology to the Asian population with impressive results. The size of the previous generation VAD was a major issue for our patients.”
Dr. Cumaraswarmy Sivathasan
Program Director, Mechanical Heart Device Program
Co-Director, Heart and Lung Transplant Program
National Heart Center, Singapore
Five Continents. 254 Centers.* HeartMate II has quickly become the gold standard pump, not just in the United States but on a global scale as well. This growth has been disciplined—for each new center, Thoratec provides the same, unrivaled level of service and clinical support. But it’s been steady, and there’s more to come. 2011 will see a continued drive to build the Destination Therapy market in Europe, a regulatory submission for HeartMate II in Japan, commercial expansion in Australia, and the first HeartMate II implants in Korea and India.
There are over 5 million heart failure patients in the United States.1 But there are millions more worldwide. Our mission extends to them all.
* As of the end of 2010.
1 Heart Disease and Stroke Statistics—2010 Update, American Heart Association